Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 8 Aug 2022 |
| Total number of shares and voting rights in Zealand Pharma at June 30, 2022 | 30 Jun 2022 |
| Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities | 15 Jun 2022 |
| Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 | 10 Jun 2022 |
| Zealand Pharma completes registration of capital increase | 3 Jun 2022 |